Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 20210493, 20220899 | Other Grant/Funding Number | Swedish Heart and Lung Foundation | |
| 2022-005109, 2025-02741 | Other Grant/Funding Number | Swedish Research Council | |
| 2019-00438 | Other Grant/Funding Number | Swedish ResearchCouncil for Health, Working Life and Welfare | |
| 20200139 | Other Grant/Funding Number | Region Stockholm | |
| 2020-01361, 2022-01675 | Other Grant/Funding Number | Karolinska Institutet |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Region Stockholm | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The overall aim of this study is to evaluate the efficacy and cost-effectiveness of a lifestyle intervention to improve lifestyle habits and reduce cardiometabolic risk factors in individuals with obsessive-compulsive disorder (OCD).
Obsessive-compulsive disorder (OCD) is a prevalent and impairing disorder with an increased risk of morbidity and mortality due to cardiometabolic diseases. These risks remain significant over and above psychiatric comorbidities and shared familial factors, indicating that at least part of this risk could be a consequence of pernicious lifestyle habits (e.g., physical inactivity, unhealthy diet). A lifestyle intervention targeting cardiometabolic risk factors in people with OCD has previously been deemed feasible, acceptable, and safe. However, the efficacy and cost-effectiveness of the intervention need to be investigated. This will be the first RCT to examine the effects of a lifestyle intervention on the health and well-being of people with OCD.
The specific aims are:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active intervention | Experimental | The lifestyle intervention (LIFT) consists of one initial individual session to create a personal plan and set up goals for a change of lifestyle habits (week 1) and 12 weekly group sessions (weeks 2 to 13) including both education on lifestyle habits and physical exercise. After week 13, participants get access to a booster module in a digital platform to help them maintain their behavioral changes. |
|
| Medical and lifestyle advice | Active Comparator | Participants in this arm will receive one individual session where participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk (week 1). Additionally, participants will receive written educational information on healthy lifestyle habits. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A group-based lifestyle intervention for individuals with OCD | Behavioral | Participants will take part in 13 week program, with one individual session to set up goals for a change of lifestyle habits, based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk, and 12 group sessions, consisting of both education on lifestyle habits and physical exercise. Each educational session will focus on a specific topic/lifestyle habit, alternating more informative sessions with sessions discussing how the information can be applied, taking into account specific hinders due to Obsessive-Compulsive Disorder. Between-sessions homework will include, for example, daily registration of physical activity and implementing changes in the lifestyle habits discussed during each session. All homework assignments will be registered in a digital platform. After the 13 weeks of lifestyle intervention, participants will get access to a booster module in the digital platform to help them maintain their behavioral changes. |
| Measure | Description | Time Frame |
|---|---|---|
| Physical activity: Steps per day | Measured as change in steps/day with an accelerometer. Participants will be asked to wear an accelerometer (activPAL™) 24 hours/day for seven consecutive days at each assessment point. The device is placed on the thigh. Data will be considered valid if wear time is ≥10 hours/day for at least 4 days, including at least one weekend day. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Measure | Description | Time Frame |
|---|---|---|
| Physical activity: Moderate to vigorous physical activity (MVPA) | MVPA per day operationalised as a walking cadence of >100 steps/minute. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| International Physical Activity Questionnaire, short form (IPAQ-SF) |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | Measured with a short questionnaire created by the research team regarding potential adverse events (e.g., increased anxiety, headaches, increased tiredness, musculoskeletal pain). They will also be able to write own examples on negative experiences connected to participation in the intervention. | Week 7 after the start of the intervention, week 14 after the start of the intervention (primary endpoint). |
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sofia Asplund, MSc | Contact | 0046706965597 | 0046706965597 | sofia.asplund@ki.se |
| Anna Holmberg, MSc | Contact | 0046739741584 | anna.holmberg.2@ki.se |
| Name | Affiliation | Role |
|---|---|---|
| Lorena Fernández de la Cruz, PhD | Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| OCD-Programmet, Psykiatri Sydväst | Recruiting | Huddinge | Stockholm County | 141 57 | Sweden |
The investigators may potentially share trial data from the study with other researchers around the world. The use would primarily be to combine outcome data for potential meta-analyses in this research field. Shared data will be pseudonymised. The possibility of future data sharing is mentioned in the informed consent form.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Medical and lifestyle advice | Behavioral | One individual session with a clinical psychologist on week 1 of about 1 hour of duration. During this session, participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk. Participants also receive written educational information on healthy lifestyle habits based on national Swedish guidelines issued by the National Board of Health and Welfare. The recommendations include engaging in regular physical activity, dietary guidelines based on Nordic Nutrition Recommendations, and advice to reduce alcohol consumption and quit tobacco use. |
|
Self-reported assessment of physical activity (moderately intense activities, vigorously intense activities, walking) and sedentary time during the last 7 days. Responses on each physical activity intensity question will be converted to metabolic equivalent of task (MET) minutes, using the formula from the IPAQ scoring protocol. Both the continuous and categorical scores (high, moderate, and low) will be calculated according to the scoring guidelines. A higher MET score corresponds to higher levels of physical activity. |
| Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| 15-item Food Frequency Questionnaire (FFQ) | Self-reported assessment of dietary patterns. It consists of 15 items concerning dietary choices, where each item is evaluated as either meeting or not meeting the guidelines set in the Nordic Nutrition Recommendations (NNR). Each met recommendation receives 1 point, resulting in a healthy eating index ranging from 0 to 15 points. Based on this index, dietary patterns are classified as good (9 or more points), average (6-8 points) or poor (5 or fewer points). | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Alcohol Use Disorder Identification Test for Consumption (AUDIT-C) | Self-reported assessment of alcohol consumption. Scores in the AUDIT-C range from 0 to 12 points, where 0 points indicate no alcohol use. Cut-off scores for risk consumption vary across settings and population, but a score ≥4 points has been suggested as a cut-off for detecting risk consumption of alcohol when validated in the general population. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Tobacco use | Evaluated by asking self-reported questions about current or previous use of cigarettes, snus or other tobacco or nicotine products. If current use, or if they quit during the last 6 months, participants are asked to specify frequency (daily, sometimes) and amount used. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Perceived Stress Scale (PSS) | Self-reported assessment of perceived stress. The total score ranges from 0 to 40, with higher scores indicating higher levels of perceived stress. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Insomnia Severity Scale (ISI) | Self-reported assessment of sleep problems and severity of symptoms. Consists of 7 items that are rated on a 5-point Likert scale to evaluate sleep problems and severity of symptoms. The total score ranges from 0 to 28 points, with a higher score indicating more severe sleep problems. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Yale-Brown Obsessive Compulsive Scale (Y-BOCS) | Clinician-rated semi-structured interview to assess OCD symptom severity. The Y-BOCS consists of 10 items rated from 0 to 4, with a total score from 0 to 40, where a higher score corresponds to more severe OCD. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Obsessive-Compulsive Inventory - 12 (OCI-12) | Self-reported assessment of OCD symptoms. Consists of 12 items rated on a 5-point Likert scale, with total scores ranging from 0-48. Scores between 0 and 12 indicate mild, between 13 and 21 indicate moderate, and between 22 and 48 indicate severe OCD symptoms. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Patient Health Questionnaire (PHQ-9) | Self-reported assessment of symptoms of depression. In this 9-item scale the total score ranges from 0 to 27 points, with a higher score corresponding to more severe symptoms of depression. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| EuroQol five dimensional five level questionnaire (EQ-5D-5L) | Self-rated assessment of own health status in five dimensions (mobility; self-care; usual activities; pain/discomfort; and anxiety/depression), within five levels of severity (no problems; slight problems; moderate problems; severe problems; or extreme problems). The scale also comprises a rating of their overall health status on a scale from 0-100 (0 = worst imaginable health; 100 = best imaginable health), the EQ-VAS scale. The scores are combined to calculate a health utility number, with the health utilities ranging from -0.31 for the worst to 1 for the best EQ-5D-5L states in Sweden. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Work and Social Adjustment Scale (WSAS) | Self-reported assessment of impairment in functioning, in terms of work, home management, social leisure activities, private leisure activities, and relationships. Each item is rated on a scale from 0 to 8, with the total score ranging from 0 to 40. A higher score corresponds to more impairment in functioning. | Baseline, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| Waist circumference | Measured in a standing position, midway between the lower rib margin and the iliac crest, in centimeters (cm) at the nearest 0.5 cm. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Sagittal abdominal diameter | Measured in a supine position at the nearest 0.1 centimeter with a ruler and a water lever or a caliper, at the level of the umbilical. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Weight | Measured in kilograms, to the nearest 0.1 kg. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Body Mass Index (BMI) | Derived by dividing weight (in kilograms measured to the nearest 0.1 kg) by height (in meters measured to the nearest 0.1 cm) squared. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Systolic and diastolic blood pressure | Measured in a seated position after ten minutes of rest, with a standard sphygmomanometer. The measurement will be taken twice with 1 minute between measures, according to the gold standard for measuring blood pressure. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Resting heart rate | Measured in a seated position following a 5 minute rest. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Total cholesterol | Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| S-low density lipoprotein cholesterol | Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| S-high density lipoprotein cholesterol | Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as mmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Lipoprotein (a) | Blood will be drawn following an overnight fast (minimum 8 hours, or else rescheduled). Measured as nmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Fasting triglycerides | Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Fasting plasma glucose | Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mmol/l. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Glycated hemoglobin | Blood will be drawn following an overnight fast (minimum 8 hours) (HbA1c, mmol/l). It reflects average plasma glucose over the previous 8-12 weeks. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Thyroid stimulating hormone (TSH) | Blood will be drawn following an overnight fast (minimum 8 hours). Measured as mE/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Cobalamin | Blood will be drawn following an overnight fast (minimum 8 hours). Reflects vitamin B12 status. Measured in pmol/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Homocysteine | Blood will be drawn following an overnight fast (minimum 8 hours). Measured in µmol/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| 25-OHD-vitamin | Blood will be drawn following an overnight fast (minimum 8 hours). Main marker of vitamin D status in the body, reported in nmol/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Folate | Blood will be drawn following an overnight fast (minimum 8 hours). Reported in nmol/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Iron deposits: Iron | Blood will be drawn following an overnight fast (minimum 8 hours). Iron [Fe], reported in µmol/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| Iron deposits: Transferrin | Blood will be drawn following an overnight fast (minimum 8 hours). Reported in µg/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| High-sensitive C-reactive protein (CRP) | Blood will be drawn following an overnight fast (minimum 8 hours). Reported in mg/L. | Baseline, week 14 after the start of the intervention (primary endpoint), 12 months after the primary endpoint. |
| White blood cell telomere length | Blood will be drawn following an overnight fast (minimum 8 hours). Telomere length in leukocytes will be measured, reported as relative telomere length (T/S ratio). | Baseline, week 14 after the start of the intervention (primary endpoint). |
| Inflammation panel | Blood will be drawn following an overnight fast (minimum 8 hours). Immune activity plasma proteins (n=92) will be analysed using the Olink Target 96 Inflammation panel. | Baseline, week 14 after the start of the intervention (primary endpoint). |
| Extracellular vesicles (EVs) | Blood will be drawn following an overnight fast (minimum 8 hours). EVs will be isolated from plasma using differential ultracentrifugation. Quantification and separation of EVs will be performed using flow cytometry using antibodies specifically marking EVs with regards to being a microparticle and their tissue of origin. We will investigate the amount and origin of EVs from the vascular endothelium, leukocytes, platelets, and the skeletal muscle. To assess the cargo of particularly interesting EVs, RNA will be isolated and miRNA profiled using the robust and high-throughput nCounter (Nanostring). | Baseline, week 14 after the start of the intervention (primary endpoint). |
| Biological age | Blood will be drawn following an overnight fast (minimum 8 hours). DNA will be extracted using the Chemagen kits on the Hamilton ChemagicSTAR® platform. Bisulfite conversion will be conducted using the EZ-96 DNA Methylation-Lightning Kit (D5033). The Illumina Infinium MethylationEPIC v.2 array will be used to quantify DNAm at ~930,000 sites. Raw methylation data will be pre-processed using standard quality control steps, including removal of low-quality probes (e.g., detection p-value >0.01), background correction, and normalization. Biological aging patterns will be assessed through epigenetic age calculations using state-of-the-art algorithms (e.g., GrimAge). Accelerated biological age will be calculated as the residual from regressing epigenetic age on chronological age. | Baseline, week 14 after the start of the intervention (primary endpoint). |
| Concurrent interventions | At each measurement point, information will be collected on any treatment changes (e.g., changes in medication, initiation of psychological treatment) and/or initiation of concurrent interventions to improve lifestyle habits (including e.g., vitamin supplements) or cardiometabolic risk factors. | Baseline, week 7 after the start of the intervention, week 14 after the start of the intervention (primary endpoint), 3 months after the primary endpoint, 6 months after the primary endpoint, 12 months after the primary endpoint. |
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| D057185 | Sedentary Behavior |
| D009043 | Motor Activity |
| D002318 | Cardiovascular Diseases |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
| D001519 | Behavior |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided